Pharma RSS Digest - 2026-05-31
Overview
The 48-hour window was light but anchored by two ASCO 2026 presentations with divergent regulatory implications. Whitehawk Therapeutics validated a novel ADC target (SEZ6) in small cell lung cancer, positioning its biparatopic candidate HWK-206 for an IND submission mid-year, while GRAIL's landmark NHS-Galleri trial delivered clinically meaningful stage shift data despite missing its primary endpoint—a pattern that regulators often weigh differently than pure statistical significance. The broader ASCO traffic continues to surface ADC combination data (Kelun-Biotech's sac-TMT) and next-generation targeted therapies (Dizal's EGFR TKI, Kelun-Biotech's RET inhibitor), reflecting persistent oncology innovation themes. The absence of FDA actions or major pipeline setbacks keeps the regulatory calendar quiet heading into the summer months.
Key Developments
Whitehawk Therapeutics presented real-world RNA analysis at ASCO 2026 confirming that SEZ6 is highly expressed across small cell lung cancer and other neuroendocrine tumors—at least 3-fold higher than established ADC targets like HER2, B7-H3, and DLL3. The expression was particularly concentrated in the SCLC-A and SCLC-N subtypes, which account for roughly 90% of cases, and correlated positively with DLL3, suggesting combination potential. The company's biparatopic ADC candidate HWK-206 uses dual epitope binding to potentially overcome first-generation ADC limitations, with IND submission targeted for mid-2026 and Phase 1 initiation in Q3 2026. This validates Whitehawk's strategy of applying advanced ADC technology to a target with high unmet need in a disease with limited treatment options. Watch for the IND filing and whether the company can secure partnership or capital to fund the Phase 1 trial.
Whitehawk Therapeutics fda approval update
GRAIL reported full results from the NHS-Galleri trial (142,250 participants ages 50-77) showing a 26% reduction in Stage IV cancer diagnoses by the third annual screen and an overall 14% reduction across three years. While the primary endpoint of combined Stage III/IV reduction was not met (IRR=1.03, p=0.63), the secondary endpoint of Stage IV reduction achieved nominal significance, and the intervention arm showed a 4-fold increase in screen-detected cancers, a 21% reduction in symptomatic diagnoses, and a 25% reduction in emergency presentations. Stage I/II diagnoses rose 16%, with particularly strong shifts for ovarian, esophageal, pancreatic, and liver cancers. The results strengthen GRAIL's commercial case for Galleri and could influence reimbursement decisions, though mortality data remain pending and longer follow-up may be needed to assess durable stage shift. Watch for regulatory submissions leveraging these data and whether the NHS expands the program.
Watchlist
- Sichuan Kelun-Biotech's Phase III OptiTROP-Lung05 trial demonstrated sacituzumab tirumotecan (TROP2 ADC) plus pembrolizumab reduced disease progression risk by 65% (HR=0.35) versus pembrolizumab alone in first-line PD-L1-positive NSCLC, with 12-month PFS of 62.4% versus 29.0%; results published simultaneously in The Lancet. [link]
- Dizal's fourth-generation EGFR TKI DZD6008 showed 82.1% tumor shrinkage in third-generation TKI-relapsed NSCLC with EGFR C797X mutations, including strong intracranial activity in patients with baseline brain metastases; golidocitinib plus anti-PD-1 also showed durable efficacy in treatment-naïve NSCLC without driver mutations. [link]
- Kelun-Biotech's lunbotinib fumarate (A400/EP0031) achieved 81.3% ORR in treatment-naïve and 87.1% ORR in pre-treated RET fusion-positive NSCLC patients, with an NMPA NDA already accepted and an FDA-cleared Phase II trial recruiting internationally. [link]